I have to wonder....... What if the ARDS trial data comes out positive, before the Type A conflict resolution is resolved. It was mentioned in the Webex, and Si hinted that the data should be able to be used as further trial data - it would simply involve gathering the data.
With all the 40 different end points, and biomarkers being accurately measured and tracked, surely there will be enough data to positively prove the manufacturing quality assays are appropriate, that there is proof via biomarkers of efficacy even when confounded by best standard of care and where diseases are similar but not the same.
Would that be proof enough for the conflict resolution boss to overturn his subordinates decision?
Is that link enough to justify the efficacy link in GvHD ?
TYPE A OUTCOME AND NOVARTIS PARTNERSHIP, page-81
-
- There are more pages in this discussion • 31 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
-0.030(2.03%) |
Mkt cap ! $1.655B | |||
| Open | High | Low | Value | Volume |
| $1.48 | $1.51 | $1.43 | $6.613M | 4.498M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2482 | $1.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.46 | 27045 | 2 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |